All the Active Ingredient Drugs
Protein Kinase Inhibitor. Bosutinib 100, 400, 500 mg. F.C. TABS.: 28 x 100 mg, 400 mg, 500 mg. Newly-diagn. CP Ph+ CML: The recommend. dose is 400×1/d.
CP, AP, or BP Ph+ CML with resistance or intoler.to prior ther.: The recomm. dose is 500 mg×1/d. Doses greater than 600 mg/day have not been studied and therefore should not be given. See lit.
Tmt. of adult pts. with: Newly-diagn. chron. phase (CP) Philadelphia chromos.-posit. chron. myelogenous leukaem. (Ph+ CML).
Chron. phase (CP), acceler. phase (AP), and blast phase (BP) Philadelphia chromos. posit. chron. myelogenous leukaem. (Ph+ CML) prev. treated with one/more tyrosine kinase inhib.(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropr. tmt. options.
C/I: Hypersens., Hepatic impair.
